

# Jeffrey S Berger

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1540882/publications.pdf>

Version: 2024-02-01

257  
papers

16,141  
citations

20797

60  
h-index

19726

117  
g-index

270  
all docs

270  
docs citations

270  
times ranked

19490  
citing authors

#	ARTICLE	IF	CITATIONS
1	Initial Invasive or Conservative Strategy for Stable Coronary Disease. <i>New England Journal of Medicine</i> , 2020, 382, 1395-1407.	13.9	1,508
2	Therapeutic Anticoagulation with Heparin in Noncritically Ill Patients with Covid-19. <i>New England Journal of Medicine</i> , 2021, 385, 790-802.	13.9	778
3	Therapeutic Anticoagulation with Heparin in Critically Ill Patients with Covid-19. <i>New England Journal of Medicine</i> , 2021, 385, 777-789.	13.9	712
4	Aspirin for the Primary Prevention of Cardiovascular Events in Women and Men. <i>JAMA - Journal of the American Medical Association</i> , 2006, 295, 306.	3.8	681
5	Thrombosis in Hospitalized Patients With COVID-19 in a New York City Health System. <i>JAMA - Journal of the American Medical Association</i> , 2020, 324, 799.	3.8	660
6	Ticagrelor versus Clopidogrel in Symptomatic Peripheral Artery Disease. <i>New England Journal of Medicine</i> , 2017, 376, 32-40.	13.9	494
7	Megakaryocytes and platelet-fibrin thrombi characterize multi-organ thrombosis at autopsy in COVID-19: A case series. <i>EclinicalMedicine</i> , 2020, 24, 100434.	3.2	465
8	Sex Differences in Mortality Following Acute Coronary Syndromes. <i>JAMA - Journal of the American Medical Association</i> , 2009, 302, 874.	3.8	440
9	Management of Coronary Disease in Patients with Advanced Kidney Disease. <i>New England Journal of Medicine</i> , 2020, 382, 1608-1618.	13.9	310
10	Aspirin for the Prevention of Cardiovascular Events in Patients With Peripheral Artery Disease. <i>JAMA - Journal of the American Medical Association</i> , 2009, 301, 1909.	3.8	302
11	Perioperative Major Adverse Cardiovascular and Cerebrovascular Events Associated With Noncardiac Surgery. <i>JAMA Cardiology</i> , 2017, 2, 181.	3.0	268
12	C-reactive protein and clinical outcomes in patients with COVID-19. <i>European Heart Journal</i> , 2021, 42, 2270-2279.	1.0	255
13	Metal pollutants and cardiovascular disease: Mechanisms and consequences of exposure. <i>American Heart Journal</i> , 2014, 168, 812-822.	1.2	245
14	Association Between Advanced Age and Vascular Disease in Different Arterial Territories. <i>Journal of the American College of Cardiology</i> , 2013, 61, 1736-1743.	1.2	227
15	International Study of Comparative Health Effectiveness with Medical and Invasive Approaches (ISCHEMIA) trial: Rationale and design. <i>American Heart Journal</i> , 2018, 201, 124-135.	1.2	202
16	Low-Dose Aspirin in Patients with Stable Cardiovascular Disease: A Meta-analysis. <i>American Journal of Medicine</i> , 2008, 121, 43-49.	0.6	195
17	Impact of Clopidogrel in Patients With Acute Coronary Syndromes Requiring Coronary Artery Bypass Surgery. <i>Journal of the American College of Cardiology</i> , 2008, 52, 1693-1701.	1.2	186
18	Current and novel biomarkers of thrombotic risk in COVID-19: a Consensus Statement from the International COVID-19 Thrombosis Biomarkers Colloquium. <i>Nature Reviews Cardiology</i> , 2022, 19, 475-495.	6.1	180

#	ARTICLE	IF	CITATIONS
19	Screening for Cardiovascular Risk in Asymptomatic Patients. <i>Journal of the American College of Cardiology</i> , 2010, 55, 1169-1177.	1.2	169
20	Neutrophil-derived S100 calcium-binding proteins A8/A9 promote reticulated thrombocytosis and atherogenesis in diabetes. <i>Journal of Clinical Investigation</i> , 2017, 127, 2133-2147.	3.9	166
21	Effect of a Home-Based Exercise Intervention of Wearable Technology and Telephone Coaching on Walking Performance in Peripheral Artery Disease. <i>JAMA - Journal of the American Medical Association</i> , 2018, 319, 1665.	3.8	151
22	Missed Opportunities. <i>Circulation</i> , 2012, 126, 1345-1354.	1.6	147
23	Hemorrhagic stroke and anticoagulation in COVID-19. <i>Journal of Stroke and Cerebrovascular Diseases</i> , 2020, 29, 104984.	0.7	147
24	Underuse of Prevention and Lifestyle Counseling in Patients With Peripheral Artery Disease. <i>Journal of the American College of Cardiology</i> , 2017, 69, 2293-2300.	1.2	140
25	Prevalence and Outcomes of D-Dimer Elevation in Hospitalized Patients With COVID-19. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2020, 40, 2539-2547.	1.1	134
26	Aspirin Attenuates Platelet Activation and Immune Activation in HIV-1-Infected Subjects on Antiretroviral Therapy. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2013, 63, 280-288.	0.9	132
27	Perioperative Cardiovascular Risk Assessment and Management for Noncardiac Surgery. <i>JAMA - Journal of the American Medical Association</i> , 2020, 324, 279.	3.8	131
28	Aspirin for the prevention of cardiovascular events in patients without clinical cardiovascular disease: A meta-analysis of randomized trials. <i>American Heart Journal</i> , 2011, 162, 115-124.e2.	1.2	125
29	Primary Prevention of Cardiovascular Disease in Diabetes Mellitus. <i>Journal of the American College of Cardiology</i> , 2017, 70, 883-893.	1.2	125
30	Smoking, Clopidogrel, and Mortality in Patients With Established Cardiovascular Disease. <i>Circulation</i> , 2009, 120, 2337-2344.	1.6	123
31	The Relative Efficacy and Safety of Clopidogrel in Women and Men. <i>Journal of the American College of Cardiology</i> , 2009, 54, 1935-1945.	1.2	119
32	Peripheral arterial disease, prevalence and cumulative risk factor profile analysis. <i>European Journal of Preventive Cardiology</i> , 2014, 21, 704-711.	0.8	112
33	Ticagrelor Compared With Clopidogrel in Patients With Prior Lower Extremity Revascularization for Peripheral Artery Disease. <i>Circulation</i> , 2017, 135, 241-250.	1.6	111
34	Platelets contribute to disease severity in COVID-19. <i>Journal of Thrombosis and Haemostasis</i> , 2021, 19, 3139-3153.	1.9	111
35	The Relationship Between Diabetes, Metabolic Syndrome, and Platelet Activity as Measured by Mean Platelet Volume. <i>Diabetes Care</i> , 2012, 35, 1074-1078.	4.3	110
36	Mean platelet volume and prevalence of peripheral artery disease, the National Health and Nutrition Examination Survey, 1999-2004. <i>Atherosclerosis</i> , 2010, 213, 586-591.	0.4	107

#	ARTICLE	IF	CITATIONS
37	The long noncoding RNA CHROME regulates cholesterol homeostasis in primates. <i>Nature Metabolism</i> , 2019, 1, 98-110.	5.1	104
38	Association of Sex With Severity of Coronary Artery Disease, Ischemia, and Symptom Burden in Patients With Moderate or Severe Ischemia. <i>JAMA Cardiology</i> , 2020, 5, 773.	3.0	101
39	Association Between Anemia, Bleeding, and Transfusion with Long-term Mortality Following Noncardiac Surgery. <i>American Journal of Medicine</i> , 2016, 129, 315-323.e2.	0.6	100
40	Perioperative acute myocardial infarction associated with non-cardiac surgery. <i>European Heart Journal</i> , 2017, 38, 2409-2417.	1.0	98
41	Myocardial Injury After Noncardiac Surgery: A Systematic Review and Meta-Analysis. <i>Cardiology in Review</i> , 2019, 27, 267-273.	0.6	94
42	Reproductive Risk Factors and Coronary Heart Disease in the Women's Health Initiative Observational Study. <i>Circulation</i> , 2016, 133, 2149-2158.	1.6	93
43	Diagnosis and Management of Patients With Myocardial Injury After Noncardiac Surgery: A Scientific Statement From the American Heart Association. <i>Circulation</i> , 2021, 144, e287-e305.	1.6	92
44	Safety and feasibility of adjunctive antiplatelet therapy with intravenous elinogrel, a direct-acting and reversible P2Y12 ADP-receptor antagonist, before primary percutaneous intervention in patients with ST-elevation myocardial infarction: The Early Rapid ReversAl of Platelet ThromboSis with Intravenous Elinogrel before PCI to Optimize REperfusion in Acute Myocardial Infarction (ERASE MI) pilot trial. <i>American Heart Journal</i> , 2009, 158, 998-1004.e1.	1.2	89
45	Effect of P2Y12 Inhibitors on Survival Free of Organ Support Among Non-Critically Ill Hospitalized Patients With COVID-19. <i>JAMA - Journal of the American Medical Association</i> , 2022, 327, 227.	3.8	89
46	Platelet and Vascular Biomarkers Associate With Thrombosis and Death in Coronavirus Disease. <i>Circulation Research</i> , 2020, 127, 945-947.	2.0	88
47	Platelet regulation of myeloid suppressor of cytokine signaling 3 accelerates atherosclerosis. <i>Science Translational Medicine</i> , 2019, 11, .	5.8	85
48	Myocardial Infarction in the ISCHEMIA Trial. <i>Circulation</i> , 2021, 143, 790-804.	1.6	81
49	Acute Limb Ischemia in Peripheral Artery Disease. <i>Circulation</i> , 2019, 140, 556-565.	1.6	80
50	The prevalence of carotid artery stenosis varies significantly by race. <i>Journal of Vascular Surgery</i> , 2013, 57, 327-337.	0.6	79
51	Rap1 and its effector RIAM are required for lymphocyte trafficking. <i>Blood</i> , 2015, 126, 2695-2703.	0.6	78
52	Platelets amplify endotheliopathy in COVID-19. <i>Science Advances</i> , 2021, 7, eabh2434.	4.7	78
53	Activated Platelets Induce Endothelial Cell Activation via an Interleukin-1 $\beta$ Pathway in Systemic Lupus Erythematosus. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2017, 37, 707-716.	1.1	77
54	and Plaque Inflammation. <i>Circulation</i> , 2019, 140, 1170-1184.	1.6	76

#	ARTICLE	IF	CITATIONS
55	Modifiable risk factor burden and the prevalence of peripheral artery disease in different vascular territories. <i>Journal of Vascular Surgery</i> , 2013, 58, 673-681.e1.	0.6	75
56	Heparin-induced thrombocytopenia (HIT): Review of incidence, diagnosis, and management. <i>Vascular Medicine</i> , 2020, 25, 160-173.	0.8	74
57	Thromboelastography Profiles of Critically Ill Patients With Coronavirus Disease 2019. <i>Critical Care Medicine</i> , 2020, 48, 1319-1326.	0.4	71
58	Medical Therapy in Peripheral Artery Disease. <i>Circulation</i> , 2012, 126, 491-500.	1.6	70
59	Circulating monocyte-platelet aggregates are a robust marker of platelet activity in cardiovascular disease. <i>Atherosclerosis</i> , 2019, 282, 11-18.	0.4	70
60	Polyvascular Disease and Risk of Major Adverse Cardiovascular Events in Peripheral Artery Disease. <i>JAMA Network Open</i> , 2018, 1, e185239.	2.8	68
61	The Changing Landscape of Diabetes Therapy for Cardiovascular Risk Reduction. <i>Journal of the American College of Cardiology</i> , 2018, 72, 1856-1869.	1.2	68
62	Trends in cardiovascular risk factor and disease prevalence in patients undergoing non-cardiac surgery. <i>Heart</i> , 2018, 104, 1180-1186.	1.2	66
63	Inflammasome Signaling and Impaired Vascular Health in Psoriasis. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2019, 39, 787-798.	1.1	66
64	Cardiovascular and Limb Outcomes in Patients With Diabetes and Peripheral Artery Disease. <i>Journal of the American College of Cardiology</i> , 2018, 72, 3274-3284.	1.2	64
65	Platelet activity and cardiovascular risk in apparently healthy individuals: a review of the data. <i>Journal of Thrombosis and Thrombolysis</i> , 2011, 32, 201-208.	1.0	61
66	Cardiovascular Risk in Patients With Psoriasis. <i>Journal of the American College of Cardiology</i> , 2021, 77, 1670-1680.	1.2	61
67	Effect of Colchicine on Platelet-Platelet and Platelet-Leukocyte Interactions: a Pilot Study in Healthy Subjects. <i>Inflammation</i> , 2016, 39, 182-189.	1.7	59
68	A Randomized Placebo Controlled Trial of Aspirin Effects on Immune Activation in Chronically Human Immunodeficiency Virus-Infected Adults on Virologically Suppressive Antiretroviral Therapy. <i>Open Forum Infectious Diseases</i> , 2017, 4, ofw278.	0.4	58
69	Thrombosis in hospitalized patients with viral respiratory infections versus COVID-19. <i>American Heart Journal</i> , 2021, 231, 93-95.	1.2	57
70	Neutrophil Subsets, Platelets, and Vascular Disease in Psoriasis. <i>JACC Basic To Translational Science</i> , 2019, 4, 1-14.	1.9	56
71	Activated Platelets Induce Endothelial Cell Inflammatory Response in Psoriasis via COX-1. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2020, 40, 1340-1351.	1.1	56
72	Risk factors for intracerebral hemorrhage in patients with COVID-19. <i>Journal of Thrombosis and Thrombolysis</i> , 2021, 51, 953-960.	1.0	56

#	ARTICLE	IF	CITATIONS
73	Cardiovascular Outcomes of Patients With Pulmonary Hypertension Undergoing Noncardiac Surgery. <i>American Journal of Cardiology</i> , 2019, 123, 1532-1537.	0.7	54
74	Chronic stress primes innate immune responses in mice and humans. <i>Cell Reports</i> , 2021, 36, 109595.	2.9	53
75	Lipid and Lipoprotein Biomarkers and the Risk of Ischemic Stroke in Postmenopausal Women. <i>Stroke</i> , 2012, 43, 958-966.	1.0	52
76	Platelet-Derived MRP-14 Induces Monocyte Activation in Patients With Symptomatic Peripheral Artery Disease. <i>Journal of the American College of Cardiology</i> , 2018, 71, 53-65.	1.2	51
77	Initial Aspirin Dose and Outcome Among ST-Elevation Myocardial Infarction Patients Treated With Fibrinolytic Therapy. <i>Circulation</i> , 2008, 117, 192-199.	1.6	49
78	Co-existence of vascular disease in different arterial beds: Peripheral artery disease and carotid artery stenosis – Data from Life Line Screening®. <i>Atherosclerosis</i> , 2015, 241, 687-691.	0.4	45
79	Reporting and representation of race/ethnicity in published randomized trials. <i>American Heart Journal</i> , 2009, 158, 742-747.	1.2	44
80	Perioperative Management to Reduce Cardiovascular Events. <i>Circulation</i> , 2016, 133, 1125-1130.	1.6	44
81	Mean Platelet Volume and Long-Term Mortality in Patients Undergoing Percutaneous Coronary Intervention. <i>American Journal of Cardiology</i> , 2013, 111, 185-189.	0.7	43
82	Thrombotic and bleeding complications after orthopedic surgery. <i>American Heart Journal</i> , 2013, 165, 427-433.e1.	1.2	43
83	Diabetes mellitus is a coronary heart disease risk equivalent for peripheral vascular disease. <i>American Heart Journal</i> , 2017, 184, 114-120.	1.2	43
84	Healthy Lifestyle and Clonal Hematopoiesis of Indeterminate Potential: Results From the Women's Health Initiative. <i>Journal of the American Heart Association</i> , 2021, 10, e018789.	1.6	43
85	Gender – Age Interaction in Early Mortality Following Primary Angioplasty for Acute Myocardial Infarction. <i>American Journal of Cardiology</i> , 2006, 98, 1140-1143.	0.7	42
86	Mean platelet volume reproducibility and association with platelet activity and anti-platelet therapy. <i>Platelets</i> , 2014, 25, 188-192.	1.1	42
87	Bleeding, mortality, and antiplatelet therapy: Results from the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHARISMA) trial. <i>American Heart Journal</i> , 2011, 162, 98-105.e1.	1.2	41
88	Design and rationale for the Effects of Ticagrelor and Clopidogrel in Patients with Peripheral Artery Disease (EUCLID) trial. <i>American Heart Journal</i> , 2016, 175, 86-93.	1.2	41
89	Combining Oral Anticoagulants With Platelet Inhibitors in Patients With Atrial Fibrillation and Coronary Disease. <i>Journal of the American College of Cardiology</i> , 2018, 72, 1790-1800.	1.2	41
90	Platelet WDR1 suppresses platelet activity and is associated with cardiovascular disease. <i>Blood</i> , 2016, 128, 2033-2042.	0.6	40

#	ARTICLE	IF	CITATIONS
91	Hospital Readmission After Perioperative Acute Myocardial Infarction Associated With Noncardiac Surgery. <i>Circulation</i> , 2018, 137, 2332-2339.	1.6	40
92	Association Between Physical Activity and Peripheral Artery Disease and Carotid Artery Stenosis in a Self-Referred Population of 3 Million Adults. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2015, 35, 206-212.	1.1	39
93	Cardiovascular Outcomes After Lower-Extremity Endovascular or Surgical Revascularization. <i>Journal of the American College of Cardiology</i> , 2018, 72, 1563-1572.	1.2	39
94	Temporal trends in initiation of VKA, rivaroxaban, apixaban and dabigatran for the treatment of venous thromboembolism - A Danish nationwide cohort study. <i>Scientific Reports</i> , 2017, 7, 3347.	1.6	36
95	Aspirin, Clopidogrel, and Ticagrelor in Acute Coronary Syndromes. <i>American Journal of Cardiology</i> , 2013, 112, 737-745.	0.7	33
96	Stroke in Patients With Peripheral Artery Disease. <i>Stroke</i> , 2019, 50, 1356-1363.	1.0	33
97	Incidence and Cost of Major Adverse Cardiovascular Events and Major Adverse Limb Events in Patients With Chronic Coronary Artery Disease or Peripheral Artery Disease. <i>American Journal of Cardiology</i> , 2019, 123, 1893-1899.	0.7	33
98	Myocardial Injury in Adults Hospitalized With COVID-19. <i>Circulation</i> , 2020, 142, 2393-2395.	1.6	33
99	Changes in High-Density Lipoprotein Cholesterol Efflux Capacity After Bariatric Surgery Are Procedure Dependent. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2018, 38, 245-254.	1.1	32
100	Physicians' Dietary Knowledge, Attitudes, and Counseling Practices: The Experience of a Single Health Care Center at Changing the Landscape for Dietary Education. <i>American Journal of Lifestyle Medicine</i> , 2019, 13, 292-300.	0.8	32
101	Diabetes and Vascular Disease in Different Arterial Territories. <i>Diabetes Care</i> , 2014, 37, 1636-1642.	4.3	31
102	Is there an association between aspirin dosing and cardiac and bleeding events after treatment of acute coronary syndrome? A systematic review of the literature. <i>American Heart Journal</i> , 2012, 164, 153-162.e5.	1.2	30
103	Sex-Specific Risks of Major Cardiovascular and Limb Events in Patients With Symptomatic Peripheral Artery Disease. <i>Journal of the American College of Cardiology</i> , 2020, 75, 608-617.	1.2	30
104	Ticagrelor versus clopidogrel in patients with symptomatic peripheral artery disease and prior coronary artery disease: Insights from the EUCLID trial. <i>Vascular Medicine</i> , 2018, 23, 523-530.	0.8	29
105	Platelet Transcriptome Profiling in HIV and ATP-Binding Cassette Subfamily C Member 4 (ABCC4) as a Mediator of Platelet Activity. <i>JACC Basic To Translational Science</i> , 2018, 3, 9-22.	1.9	28
106	Outcomes of Patients with Critical Limb Ischaemia in the EUCLID Trial. <i>European Journal of Vascular and Endovascular Surgery</i> , 2018, 55, 109-117.	0.8	28
107	Systemic Lupus Erythematosus and Increased Prevalence of Atherosclerotic Cardiovascular Disease in Hospitalized Patients. <i>Mayo Clinic Proceedings</i> , 2019, 94, 1436-1443.	1.4	28
108	Particulate Air Pollution and Carotid Artery Stenosis. <i>Journal of the American College of Cardiology</i> , 2015, 65, 1150-1151.	1.2	27

#	ARTICLE	IF	CITATIONS
109	Association of the ankle-brachial index with history of myocardial infarction and stroke. <i>American Heart Journal</i> , 2014, 167, 499-505.	1.2	26
110	Use of troponin assay 99th percentile as the decision level for myocardial infarction diagnosis. <i>American Heart Journal</i> , 2017, 190, 135-139.	1.2	26
111	Influence of Diabetes on Trends in Perioperative Cardiovascular Events. <i>Diabetes Care</i> , 2018, 41, 1268-1274.	4.3	26
112	Association of Thrombocytopenia, Revascularization, and In-Hospital Outcomes in Patients with Acute Myocardial Infarction. <i>American Journal of Medicine</i> , 2019, 132, 942-948.e5.	0.6	26
113	Incidence, Characteristics, and Outcomes of Myocardial Infarction in Patients With Peripheral Artery Disease. <i>JAMA Cardiology</i> , 2019, 4, 7.	3.0	26
114	CCL20 in psoriasis: A potential biomarker of disease severity, inflammation, and impaired vascular health. <i>Journal of the American Academy of Dermatology</i> , 2021, 84, 913-920.	0.6	26
115	Multiple Biomarker Approach to Risk Stratification in COVID-19. <i>Circulation</i> , 2021, 143, 1338-1340.	1.6	26
116	Statins and Diabetes: The Good, the Bad, and the Unknown. <i>Current Atherosclerosis Reports</i> , 2013, 15, 299.	2.0	25
117	B-Type Natriuretic Peptides Improve Cardiovascular Disease Risk Prediction in a Cohort of Women. <i>Journal of the American College of Cardiology</i> , 2014, 64, 1789-1797.	1.2	25
118	Peripheral vascular disease risk in diabetic individuals without coronary heart disease. <i>Atherosclerosis</i> , 2018, 275, 419-425.	0.4	25
119	Presentation and Management of Inferior Vena Cava Thrombosis. <i>Annals of Vascular Surgery</i> , 2019, 56, 17-23.	0.4	25
120	Chronic kidney disease and outcomes of lower extremity revascularization for peripheral artery disease. <i>Atherosclerosis</i> , 2020, 297, 149-156.	0.4	25
121	Hyperreactive platelet phenotypes: Relationship to altered serotonin transporter number, transport kinetics and intrinsic response to adrenergic co-stimulation. <i>Thrombosis and Haemostasis</i> , 2013, 109, 34-38.	1.8	24
122	Outcomes of Participants With Diabetes in the ISCHEMIA Trials. <i>Circulation</i> , 2021, 144, 1380-1395.	1.6	24
123	Relation of Perioperative Elevation of Troponin to Long-Term Mortality After Orthopedic Surgery. <i>American Journal of Cardiology</i> , 2015, 115, 1643-1648.	0.7	23
124	Cardiovascular Risk Scores to Predict Perioperative Stroke in Noncardiac Surgery. <i>Stroke</i> , 2019, 50, 2002-2006.	1.0	23
125	Incidence and Factors Associated With Major Amputation in Patients With Peripheral Artery Disease. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2020, 13, e006399.	0.9	23
126	Characterization of PCSK9 in the Blood and Skin of Psoriasis. <i>Journal of Investigative Dermatology</i> , 2021, 141, 308-315.	0.3	23



#	ARTICLE	IF	CITATIONS
127	Psoriasis and Cardiovascular Disease: Novel Mechanisms and Evolving Therapeutics. <i>Current Atherosclerosis Reports</i> , 2021, 23, 67.	2.0	23
128	Impact of renal function on ischemic stroke and major bleeding rates in nonvalvular atrial fibrillation patients treated with warfarin or rivaroxaban: a retrospective cohort study using real-world evidence. <i>Current Medical Research and Opinion</i> , 2017, 33, 1891-1900.	0.9	21
129	Elevated GlycA in severe obesity is normalized by bariatric surgery. <i>Diabetes, Obesity and Metabolism</i> , 2019, 21, 178-182.	2.2	21
130	Peripheral artery disease, biomarkers, and darapladib. <i>American Heart Journal</i> , 2011, 161, 972-978.	1.2	20
131	Greater Frequency of Fruit and Vegetable Consumption Is Associated With Lower Prevalence of Peripheral Artery Disease. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2017, 37, 1234-1240.	1.1	20
132	Safety and effectiveness of rivaroxaban and apixaban in patients with venous thromboembolism: a nationwide study. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2018, 4, 220-227.	1.4	20
133	Human low-affinity IgG receptor FcγRIIA polymorphism H131R associates with subclinical atherosclerosis and increased platelet activity in systemic lupus erythematosus. <i>Journal of Thrombosis and Haemostasis</i> , 2019, 17, 532-537.	1.9	20
134	Body mass index and peripheral artery disease. <i>Atherosclerosis</i> , 2020, 292, 31-36.	0.4	20
135	Improving the quality of care for women with cardiovascular disease. <i>American Heart Journal</i> , 2008, 156, 816-825.e1.	1.2	19
136	Aspirin Use, Dose, and Clinical Outcomes in Postmenopausal Women With Stable Cardiovascular Disease. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2009, 2, 78-87.	0.9	19
137	The Neutrophil to Lymphocyte Ratio Is Associated With the Risk of Subsequent Dementia in the Framingham Heart Study. <i>Frontiers in Aging Neuroscience</i> , 2021, 13, 773984.	1.7	19
138	Bleeding-associated outcomes with preoperative clopidogrel use in on- and off-pump coronary artery bypass. <i>Journal of Thrombosis and Thrombolysis</i> , 2012, 34, 56-64.	1.0	16
139	Use of oral anticoagulants in combination with antiplatelet(s) in atrial fibrillation. <i>Heart</i> , 2018, 104, 912-920.	1.2	16
140	Cardiovascular Risk Factor Control and Lifestyle Factors in Young to Middle-Aged Adults with Newly Diagnosed Obstructive Coronary Artery Disease. <i>Cardiology</i> , 2019, 142, 83-90.	0.6	16
141	Association of Hypertension and Arterial Blood Pressure on Limb and Cardiovascular Outcomes in Symptomatic Peripheral Artery Disease. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2020, 13, e006512.	0.9	16
142	Real-world effectiveness and safety of rivaroxaban versus warfarin among non-valvular atrial fibrillation patients with obesity in a US population. <i>Current Medical Research and Opinion</i> , 2021, 37, 881-890.	0.9	16
143	Platelet aggregation and coagulation factors in orthopedic surgery. <i>Journal of Thrombosis and Thrombolysis</i> , 2014, 38, 430-438.	1.0	15
144	Perioperative antiplatelet therapy and cardiovascular outcomes in patients undergoing joint and spine surgery. <i>Journal of Clinical Anesthesia</i> , 2016, 35, 163-169.	0.7	15

#	ARTICLE	IF	CITATIONS
145	Team Approach: Perioperative Optimization for Total Joint Arthroplasty. JBJS Reviews, 2018, 6, e4-e4.	0.8	15
146	Perioperative cardiovascular outcomes of non-cardiac solid organ transplant surgery. European Heart Journal Quality of Care & Clinical Outcomes, 2019, 5, 72-78.	1.8	15
147	Ejection fraction, B-type natriuretic peptide and risk of stroke and acute myocardial infarction among patients with heart failure. Clinical Cardiology, 2019, 42, 277-284.	0.7	15
148	Reproducibility over time and effect of low-dose aspirin on soluble P-selectin and soluble CD40 ligand. Journal of Thrombosis and Thrombolysis, 2015, 40, 83-87.	1.0	14
149	Risk of Venous Thromboembolism after New Onset Heart Failure. Scientific Reports, 2019, 9, 17415.	1.6	14
150	Anticoagulation in COVID-19: reaction to the ACTION trial. Lancet, The, 2021, 397, 2226-2228.	6.3	14
151	Platelet activation increases in patients undergoing vascular surgery. Thrombosis Research, 2014, 134, 952-956.	0.8	13
152	Lipoprotein(a) screening in patients with controlled traditional risk factors undergoing percutaneous coronary intervention. Journal of Clinical Lipidology, 2017, 11, 1177-1180.	0.6	13
153	Trends in Perioperative Venous Thromboembolism Associated with Major Noncardiac Surgery. TH Open, 2017, 01, e82-e91.	0.7	13
154	Oral Antiplatelet Therapy for Secondary Prevention of Acute Coronary Syndrome. American Journal of Cardiovascular Drugs, 2018, 18, 457-472.	1.0	13
155	Atrial Septal Defect and the Risk of Ischemic Stroke in the Perioperative Period of Noncardiac Surgery. American Journal of Cardiology, 2019, 124, 1120-1124.	0.7	13
156	Chronic kidney disease and risk for cardiovascular and limb outcomes in patients with symptomatic peripheral artery disease: The EUCLID trial. Vascular Medicine, 2019, 24, 422-430.	0.8	13
157	Risk of Ischemic Stroke in Patients Newly Diagnosed With Heart Failure: Focus on Patients Without Atrial Fibrillation. Journal of Cardiac Failure, 2019, 25, 436-447.	0.7	13
158	Cardiovascular Risk Factors and Perioperative Myocardial Infarction After Noncardiac Surgery. Canadian Journal of Cardiology, 2021, 37, 224-231.	0.8	13
159	Low-density lipoprotein aggregation predicts adverse cardiovascular events in peripheral artery disease. Atherosclerosis, 2021, 316, 53-57.	0.4	13
160	Platelet-conditioned media induces an anti-inflammatory macrophage phenotype through EP4. Journal of Thrombosis and Haemostasis, 2021, 19, 562-573.	1.9	13
161	Association of Heart Failure With Outcomes Among Patients With Peripheral Artery Disease: Insights From EUCLID. Journal of the American Heart Association, 2021, 10, e018684.	1.6	13
162	Use of novel antithrombotic agents for COVID-19: Systematic summary of ongoing randomized controlled trials. Journal of Thrombosis and Haemostasis, 2021, 19, 3080-3089.	1.9	13



#	ARTICLE	IF	CITATIONS
181	Comparison of Days Alive Out of Hospital With Initial Invasive vs Conservative Management. <i>JAMA Cardiology</i> , 2021, 6, 1023.	3.0	10
182	Aspirin as Preventive Therapy in Patients With Asymptomatic Vascular Disease. <i>JAMA - Journal of the American Medical Association</i> , 2010, 303, 880.	3.8	9
183	Changes in lipoprotein(a) following bariatric surgery. <i>American Heart Journal</i> , 2018, 197, 175-176.	1.2	9
184	Underuse of Medications and Lifestyle Counseling to Prevent Cardiovascular Disease in Patients With Diabetes. <i>Diabetes Care</i> , 2019, 42, e75-e76.	4.3	9
185	Real-World Predictors of Major Adverse Cardiovascular Events and Major Adverse Limb Events Among Patients with Chronic Coronary Artery Disease and/or Peripheral Arterial Disease. <i>Advances in Therapy</i> , 2020, 37, 240-252.	1.3	9
186	Postinjury platelet aggregation and venous thromboembolism. <i>Journal of Trauma and Acute Care Surgery</i> , 2022, 93, 604-612.	1.1	9
187	An Aspirin a Day: Are We Barking Up the Wrong Willow Tree?. <i>Pharmacotherapy</i> , 2010, 30, 115-118.	1.2	8
188	Prevalence of unrecognized diabetes, prediabetes and metabolic syndrome in patients undergoing elective percutaneous coronary intervention. <i>Diabetes/Metabolism Research and Reviews</i> , 2015, 31, 603-609.	1.7	8
189	Telephone-based mindfulness training to reduce stress in women with myocardial infarction: Rationale and design of a multicenter randomized controlled trial. <i>American Heart Journal</i> , 2018, 202, 61-67.	1.2	8
190	Systemic lupus erythematosus and the risk of perioperative major adverse cardiovascular events. <i>Journal of Thrombosis and Thrombolysis</i> , 2018, 45, 13-17.	1.0	8
191	Antithrombotic therapy in peripheral artery disease. <i>Lancet, The</i> , 2018, 391, 183-184.	6.3	8
192	Major bleeding in patients with peripheral artery disease: Insights from the EUCLID trial. <i>American Heart Journal</i> , 2020, 220, 51-58.	1.2	8
193	Antisense oligonucleotide targeting of thrombopoietin represents a novel platelet depletion method to assess the immunomodulatory role of platelets. <i>Journal of Thrombosis and Haemostasis</i> , 2020, 18, 1773-1782.	1.9	8
194	Go Red for Women Strategically Focused Research Network: Summary of Findings and Network Outcomes. <i>Journal of the American Heart Association</i> , 2021, 10, e019519.	1.6	8
195	Perioperative cardiovascular outcomes among older adults undergoing in-hospital noncardiac surgery. <i>Journal of the American Geriatrics Society</i> , 2021, 69, 2821-2830.	1.3	8
196	Periprocedural Glycemic Control in Patients With Diabetes Mellitus Undergoing Coronary Angiography With Possible Percutaneous Coronary Intervention. <i>American Journal of Cardiology</i> , 2014, 113, 1474-1480.	0.7	7
197	Perioperative bleeding and thrombotic risks in patients with Von Willebrand disease. <i>Journal of Thrombosis and Thrombolysis</i> , 2017, 44, 67-70.	1.0	7
198	Clinical outcomes of prolonged anticoagulation with rivaroxaban after unprovoked venous thromboembolism. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2018, 2, 58-68.	1.0	7

#	ARTICLE	IF	CITATIONS
199	Association of Disease Progression With Cardiovascular and Limb Outcomes in Patients With Peripheral Artery Disease. <i>Circulation: Cardiovascular Interventions</i> , 2020, 13, e009326.	1.4	7
200	Association of Health Status Scores With Cardiovascular and Limb Outcomes in Patients With Symptomatic Peripheral Artery Disease: Insights From the EUCLID (Examining Use of Ticagrelor in) Tj ETQq0 0 0 rgBT./Overlock 10 Tf 50 e016573.	1.6	7
201	Psoriasis and Cardiovascular Disease—An Ounce of Prevention Is Worth a Pound of Cure. <i>JAMA Dermatology</i> , 2022, 158, 239.	2.0	7
202	Effect of Dietary Modification on Incident Carotid Artery Disease in Postmenopausal Women. <i>Stroke</i> , 2014, 45, 1748-1756.	1.0	6
203	Rationale and design of the Investigation of Motivational Interviewing and Prevention Consults to Achieve Cardiovascular Targets (IMPACT) trial. <i>American Heart Journal</i> , 2015, 170, 430-437.e9.	1.2	6
204	Intravenous heparin dosing strategy in hospitalized patients with atrial dysrhythmias. <i>Journal of Thrombosis and Thrombolysis</i> , 2016, 42, 179-185.	1.0	6
205	Risk for Venous Thromboembolism Recurrence Among Rivaroxaban-treated Patients Who Continued Versus Discontinued Therapy: Analyses Among Patients with VTE. <i>Clinical Therapeutics</i> , 2017, 39, 1396-1408.	1.1	6
206	Investigation of Motivational Interviewing and Prevention Consults to Achieve Cardiovascular Targets (IMPACT) trial. <i>American Heart Journal</i> , 2018, 199, 37-43.	1.2	6
207	Sex differences in the prevalence of vascular disease and risk factors in young hospitalized patients with psoriasis. <i>International Journal of Women's Dermatology</i> , 2019, 5, 251-255.	1.1	6
208	Impact of Procedural Bleeding in Peripheral Artery Disease. <i>Circulation: Cardiovascular Interventions</i> , 2019, 12, e008069.	1.4	6
209	Association of Chronic Obstructive Pulmonary Disease with Morbidity and Mortality in Patients with Peripheral Artery Disease: Insights from the EUCLID Trial. <i>International Journal of COPD</i> , 2021, Volume 16, 841-851.	0.9	6
210	Summoning STRENGTH to Question the Placebo in REDUCE-IT. <i>Circulation</i> , 2021, 144, 407-409.	1.6	6
211	Low Diastolic Blood Pressure and Mortality in Older Women. Results From the Women's Health Initiative Long Life Study. <i>American Journal of Hypertension</i> , 2022, 35, 795-802.	1.0	6
212	The Role of Statin Therapy for Primary Prevention: What is the Evidence?. <i>Current Atherosclerosis Reports</i> , 2012, 14, 167-174.	2.0	5
213	Cardiovascular outcomes among elderly patients with heart failure and coronary artery disease and without atrial fibrillation: a retrospective cohort study. <i>BMC Cardiovascular Disorders</i> , 2019, 19, 19.	0.7	5
214	Risk of thrombotic events after respiratory infection requiring hospitalization. <i>Scientific Reports</i> , 2021, 11, 4053.	1.6	5
215	Sex Differences in Thrombosis and Mortality in Patients Hospitalized for COVID-19. <i>American Journal of Cardiology</i> , 2022, 170, 112-117.	0.7	5
216	Acute Myocardial Infarction Following Hospitalization for Gastrointestinal Bleeding: Incidence, Predictors, Management, and Outcomes. <i>American Journal of Medicine</i> , 2022, 135, e263-e278.	0.6	5

#	ARTICLE	IF	CITATIONS
217	Association of glycoprotein IIb/IIIa inhibitors and long-term survival following administration during percutaneous coronary intervention for acute myocardial infarction. <i>Journal of Thrombosis and Thrombolysis</i> , 2006, 21, 229-234.	1.0	4
218	Duration of Anticoagulation for Venous Thromboembolic Events. <i>Circulation</i> , 2014, 130, 2343-2348.	1.6	4
219	Characteristics and Outcomes of Type 1 versus Type 2 Perioperative Myocardial Infarction After Noncardiac Surgery. <i>American Journal of Medicine</i> , 2022, 135, 202-210.e3.	0.6	4
220	Aspirin in primary prevention: can we individualize care?. <i>Cardiovascular Diagnosis and Therapy</i> , 2012, 2, 169-72.	0.7	4
221	Outcomes With Intermediate Left Main Disease: Analysis From the ISCHEMIA Trial. <i>Circulation: Cardiovascular Interventions</i> , 2022, 15, CIRCINTERVENTIONS121010925.	1.4	4
222	Total Cardiovascular and Limb Events and the Impact of Polyvascular Disease in Chronic Symptomatic Peripheral Artery Disease. <i>Journal of the American Heart Association</i> , 2022, 11, .	1.6	4
223	Healthcare resource utilization and costs of rivaroxaban versus warfarin among non-valvular atrial fibrillation (NVAf) patients with obesity in a US population. <i>Journal of Medical Economics</i> , 2021, 24, 550-562.	1.0	3
224	Ticagrelor added to methotrexate improves rheumatoid arthritis disease severity. <i>Rheumatology</i> , 2021, 60, 5473-5475.	0.9	3
225	More frequent olive oil intake is associated with reduced platelet activation in obesity. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2021, 31, 3322-3325.	1.1	3
226	Diabetes mellitus and outcomes of lower extremity revascularization for peripheral artery disease. <i>European Heart Journal Quality of Care &amp; Clinical Outcomes</i> , 2022, 8, 298-306.	1.8	3
227	The Reply. <i>American Journal of Medicine</i> , 2016, 129, e211.	0.6	2
228	CYP2C19 status and risk of major adverse cardiovascular events in peripheral artery disease: Insights from the EUCLID Trial. <i>American Heart Journal</i> , 2020, 229, 118-120.	1.2	2
229	Microvascular endothelial glycocalyx thickness is associated with brachial artery flow-mediated dilation. <i>Vascular Medicine</i> , 2021, 26, 563-565.	0.8	2
230	Ankle-Brachial Index for Risk Stratification in Patients With Symptomatic Peripheral Artery Disease With and Without Prior Lower Extremity Revascularization: Observations From the EUCLID Trial. <i>Circulation: Cardiovascular Interventions</i> , 2021, 14, e009871.	1.4	2
231	Economic burden of rivaroxaban and warfarin among nonvalvular atrial fibrillation patients with obesity and polypharmacy. <i>Journal of Comparative Effectiveness Research</i> , 2021, 10, 1235-1250.	0.6	2
232	Etiology and outcomes of amputation in patients with peripheral artery disease in the EUCLID trial. <i>Journal of Vascular Surgery</i> , 2022, 75, 660-670.e3.	0.6	2
233	World regional differences in outcomes for patients with peripheral artery disease: Insights from the EUCLID trial. <i>Vascular Medicine</i> , 2021, , 1358863X2110386.	0.8	2
234	Is PAD a Hypercoagulable Disorder?. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2021, 41, 387-389.	1.1	2

#	ARTICLE	IF	CITATIONS
235	Risk of Venous Thromboembolism Recurrence Among Rivaroxaban Treated Patients Who Continued Versus Discontinued Therapy: Analyses Among VTE Patients. <i>Blood</i> , 2016, 128, 144-144.	0.6	2
236	Bleeding Outcomes after Noncardiac Surgery – Are We POISED to Do Better?. <i>New England Journal of Medicine</i> , 2022, 386, 2052-2053.	13.9	2
237	In reply to the letter to the editor by Paul et al. <i>American Heart Journal</i> , 2013, 165, e29.	1.2	1
238	The assessment of thrombotic markers utilizing ionic versus non-ionic contrast during coronary angiography and intervention trial. <i>Catheterization and Cardiovascular Interventions</i> , 2016, 88, 727-737.	0.7	1
239	Lipoprotein insulin resistance score in nondiabetic patients with obesity after bariatric surgery. <i>Surgery for Obesity and Related Diseases</i> , 2020, 16, 1554-1560.	1.0	1
240	To DOAC or Not to DOAC for Left Ventricular Thrombi – What Is the Dose?. <i>JAMA Cardiology</i> , 2021, 6, 603.	3.0	1
241	Abstract 16569: Psychosocial Risk Factors for Depression in Women With Myocardial Infarction: Mindfulness and Rumination. <i>Circulation</i> , 2020, 142, .	1.6	1
242	Identification of a Whole Blood Signature for Venous Thromboembolism. <i>Blood</i> , 2018, 132, 3809-3809.	0.6	1
243	Risk factors, transcriptomics, and outcomes of myocardial injury following lower extremity revascularization. <i>Scientific Reports</i> , 2022, 12, 6718.	1.6	1
244	Platelet inhibition by low-dose aspirin is not influenced by body mass or weight. <i>Platelets</i> , 0, , 1-6.	1.1	1
245	Response to Letter Regarding Article, “Smoking, Clopidogrel, and Mortality in Patients With Established Cardiovascular Disease”. <i>Circulation</i> , 2010, 122, .	1.6	0
246	Risk of Recurrences in Patients With Unprovoked VTE Who Continued vs Discontinued Rivaroxaban Therapy After 3-Month Therapy. <i>Chest</i> , 2016, 150, 1155A.	0.4	0
247	Natural History and Outcomes of Patients with Critical Limb Ischemia in the Euclid Trial. <i>European Journal of Vascular and Endovascular Surgery</i> , 2019, 58, e117-e118.	0.8	0
248	Impact of chronic kidney disease on hemoglobin among patients with peripheral artery disease treated with P2Y12 inhibitors: Insights from the EUCLID trial. <i>Vascular Medicine</i> , 2021, 26, 1358863X2110176.	0.8	0
249	Reproducibility, Pre-Analytical Variables and Effect of Aspirin On Soluble P Selectin and CD40 Ligand.. <i>Blood</i> , 2012, 120, 2255-2255.	0.6	0
250	Ticagrelor Modulates Proliferation in Multiple Myeloma Via P1 and P2 Receptor-Mediated Mechanisms. <i>Blood</i> , 2016, 128, 5694-5694.	0.6	0
251	Antiplatelet Therapy in Peripheral Artery Disease. , 2017, , 1381-1390.		0
252	Antiplatelet Therapy. <i>Contemporary Cardiology</i> , 2021, , 249-288.	0.0	0

#	ARTICLE	IF	CITATIONS
253	Cardiovascular Risk Assessment for Noncardiac Surgery—Reply. JAMA - Journal of the American Medical Association, 2020, 324, 2106.	3.8	0
254	Relation of Previous Coronary Artery Bypass Grafting and/or Percutaneous Coronary Intervention to Perioperative Cardiovascular Outcomes in Patients Who Underwent Noncardiac Surgery. American Journal of Cardiology, 2022, 170, 40-46.	0.7	0
255	Abstract 10596: Telephone-Based Stress Management in Women with Myocardial Infarction: Findings from the Go Red for Women Strategically Focused Research Network. Circulation, 2021, 144, .	1.6	0
256	Response to clopidogrel in patients undergoing lower extremity revascularization. Vascular, 2022, , 170853812211034.	0.4	0
257	Systematic review and meta-regression on the duration of LDL-C lowering and major adverse cardiovascular events. Vascular Medicine, 0, , 1358863X2210984.	0.8	0